Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects
β Scribed by B. Langner; B. Lemmer
- Publisher
- Springer
- Year
- 1988
- Tongue
- English
- Weight
- 757 KB
- Volume
- 33
- Category
- Article
- ISSN
- 0031-6970
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Following a cross-over design propranolol 20 mg p.o. was given to 7 healthy subjects at 09.00 h and 21.00 h at an interval of 1 week. Heart rate (HR) during submaximal ergometer exercise was measured at four intervals during 10 h after treatment. Plasma propranolol concentrations were also determine
Plasma levels of the partial dopamine agonist, terguride, were measured by RIA in healthy volunteers after a single i.v. dose of 50 micrograms and on the first and seventh day of an oral treatment with 250 micrograms, 500 micrograms and 750 micrograms b.d. Basal and releasing hormone (TRH, GHRH, CRF
A new radioimmunoassay (RIA) for the specific measurement of dihydroergotamine (DHE), sufficiently sensitive for the determination of low plasma concentrations, has been used to investigate the pharmacokinetics of unchanged DHE. In a randomized cross-over trial, eight healthy male volunteers receive
The pharmacokinetics of oral midazolam (Dormicum@, 15 mg) and loprazolam (Dormonoct@, 1 mg) were studied in eight healthy young volunteers in a cross-over design. Plasma concentrations of midazolam were measured with a gas chromatographic method and loprazolam concentrations were determined by a rad